

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number
WO 2013/097074 A8

(43) International Publication Date
4 July 2013 (04.07.2013)

(51) International Patent Classification:

A61K 31/519 (2006.01) *A61P 15/10* (2006.01)
A61K 9/00 (2006.01)

(21) International Application Number:

PCT/CN2011/084647

(22) International Filing Date:

26 December 2011 (26.12.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(71) Applicant (for all designated States except US):
TRITECH BIOPHARMACEUTICALS CO., LTD.
[CN/CN]; No. 45, Minsheng Rd., Tamsui Dist., New
Taipei, 251 (TW).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LIU, Yee-Chien**
[CN/CN]; No. 45, Minsheng Rd., Tamsui Dist., New
Taipei, 251 (TW). **WU, Pei-Ling** [CN/CN]; No. 45, Min-
sheng Rd., Tamsui Dist., New Taipei, 251 (TW).

(74) Agent: **SHANGHAI PATENT & TRADEMARK LAW
OFFICE, LLC**; 435 Guiping Road, Shanghai 200233
(CN).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD,
SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(48) Date of publication of this corrected version:

12 June 2014

(15) Information about Correction:

see Notice of 12 June 2014

(54) Title: METHOD AND IMPROVED PHARMACEUTICAL COMPOSITION FOR ENHANCING TRANSDERMAL DELIV-
ERY OF PDE-5 INHIBITOR

(57) Abstract: A transdermal pharmaceutical composition comprising a phosphodiesterase type-5 inhibitor or a pharmaceutically ac-
ceptable salt thereof and a pharmaceutically excipient, wherein the transdermal pharmaceutical composition comprises an enhancer
selected from the group of cocamidopropyl betaine, sodium lauroamphoacetate, quaternium-60, isostearamidopropyl morpholine
lactate, dipropylene glycol and a combination thereof.



WO 2013/097074 A8